Kornimate/medical-research-clean huggingface dataset:
evaluation of galectin-3 levels in gcf and saliva of patients with different periodontal diseases

Conditions: Periodontal Diseases

Summary: the aim of this study is to assess the levels of galectin-3 in the gcf and saliva in patient with gingivitis and patient with stage iii periodontitis.

the aim of this study is to assess the levels of galectin-3 in the gcf and saliva in patient with gingivitis and patient with stage iii periodontitis. this study will be conducted in the oral medicine and periodontology department, faculty of dentistry- cairo university, egypt. patients will be selected from the outpatient clinic of the department of oral medicine and periodontology, faculty of dentistry-cairo university.

Eligibility criteria:
inclusion criteria: 1. for healthy group: individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. 2. for the gingivitis group: individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss. 3. for the periodontitis group that has not received periodontal treatment in the last 6 months 4. for the periodontitis group: individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss. 5. presence of a minimum of 15 natural teeth. exclusion criteria: 1. individuals with any known systemic disease. 2. pregnant and lactating women. 3. individuals that received periodontal treatment within the last 6 months. 4. individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months. 5. former or current smokers.

Keywords: galectin-3
signs and symptoms associated with molecular defects in genetically inherited heart disease

Conditions: Congenital Heart Defect

Summary: genetically inherited heart diseases (familial cardiopathies) are conditions affecting the heart passed on to family members by abnormalities in genetic information. these conditions are responsible for many heart related deaths and illnesses. researchers are interested in learning more about the specific genetic abnormalities causing heart diseases. in addition, they would like to find out how these abnormal genes can contribute to the development of other medical problems. in order to do this, researchers plan to study patients and family members of patients diagnosed with genetically inherited heart disease. those people participating in the study will undergo a variety of tests including blood tests, echocardiograms, and magnetic resonance imaging studies (mri). these tests will be used to help researchers find the genetic problem causing the familial cardiopathy. researchers hope that the information gathered from this study can be used to develop better medical care through early diagnosis, management, and treatment plans.

familial cardiomyopathies (fc) are important cardiovascular causes of morbidity and mortality that demonstrate both allelic and non-allelic genetic heterogeneity. we propose to perform genetic studies to determine novel molecular causes of fc and to describe their clinical correlates. this will permit: (1) pre-symptomatic diagnosis; (2) definition of cardiac phenotype, disease penetrance; (3) natural history; (4) study of abnormal physiology that is a consequence of the molecular defect; (5) elucidation of specific mechanisms of arrythmias and sudden death; and (6) demonstration and characterization of skeletal muscle involvement.

Eligibility criteria:
inclusion and exclusion criteria the subjects will consist of family members who may have inherited fc and spouses that may help in the linkage studies. family members or spouses who do not wish to participate in the research protocol will be excluded from the study.

Keywords: genetics cardiac diseases cardiac hypertrophy sudden death arrhythmias
the lolland-falster health study

Conditions: Impaired Health; Disease; Wellbeing; Mental Disorders; Atherosclerosis; Renal Insufficiency, Chronic; Skin Diseases; Urinary Incontinence; Personality; Coronary Disease; Ear Diseases; Nose Diseases; Pharyngeal Diseases; Chronic Disease

Summary: the study is a epidemiological, cross-sectional study in a mainly rural area of denmark in denmark. life expectancy is shorter, morbidity is higher, and social problems more prevalent than in the urban areas of the country. the population study aims at examining complexities of environmental, hereditary, lifestyle, and social factors as determinants and predisposing factors for morbidity, health, and quality of life. the study will cover physical, mental, and social dimensions and examine family patterns and subgroups. the study will provide baseline information for later follow-up.


Eligibility criteria:
inclusion criteria: * individuals registered in lolland or guldborgsund municipality exclusion criteria: * adults with incapacity guardianship * incapacity to give informed consent * individuals with address protection * severe physical immobility * non-danish and non-english speaking
effects of yoga on objective and self-reported health indicators among female and male individuals

Conditions: Stress, Psychological, Physiological

Summary: the purpose of this study is to determine whether inversions (specific yoga postures in which the heart is higher than the head) and other dynamic and static yoga postures affect heart rate variability, oxygen uptake, blood pressure, blood parameters and other objective measures of health, and a variety of subjective and objective measures of health in female and male individuals in sweden.

this randomized, controlled trial involving 44 male and females in sweden will investigate whether yoga inversions and semi-inversions and other dynamic and static yoga postures will affect the following variables: heart rate variability, oxygen uptake, anthropometric variables, common symptoms in general practice, sleepiness, sleep quality and recovery/recuperation after sleep, blood pressure, blood lipids, blood proteins, blood sugar, salivary cortisol, hand grip strength, relaxation and recovery perceived stress, self-rated health, rating of perceived exertion, satisfaction with life, and work-family conflict. participants will be divided into an intervention group and a passive control group. the intervention group will participate in six to ten weeks of yoga classes. the classes will be held 1-2 times a week for approximately one hour each and will include yoga poses and breathing techniques. the control group will not participate in any intervention but will conduct their lives as usual. the variables will be assessed at baseline; at the end of the intervention; and three, six, and twelve months after the end of the intervention.

Eligibility criteria:
inclusion criteria: * aged 20-40 years old exclusion criteria: * aged 40 or more years * takes medication for high blood pressure or other strong medication * recently had an operation * diagnosed with eye disease (e.g., glaucoma) * diagnosed with depression or burnout syndrome * diagnosed with serious back or neck problems * participates in intense physical activity more than once a week * has digestive problems such as acid reflux * serious disorder that affects the ability to do the yoga postures

Keywords: heart rate variability oxygen uptake heart rate recovery perceived stress sleep blood pressure body mass index body weight hand grip strength sleep quality subjective health complaints blood lipids salivary cortisol blood sugar hba1c adiponectin leptin adipolipoproteins blood proteins cytokines insomnia sleeplessness yoga
trigeminal evoked responses to improve rhizotomy

Conditions: Trigeminal Neuralgia; Rhizotomy

Summary: trigeminal neuralgia (tgn) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. trigeminal somatosensory evoked potentials (tseps) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). while tseps have been measured in the past, it is not clear if implementing tseps into a routine neurosurgical rhizotomy procedure will be feasible. this is a prospective cohort study examining the feasibility of routinely performing tseps during rhizotomies for tgn.


Eligibility criteria:
inclusion criteria: * adults of 18 years or older * scheduled to undergo percutaneous rhizotomy for facial pain exclusion criteria: * for tgn: facial pain of unclear origin (i.e. not clearly tgn pain) or rhizotomy procedure canceled * for healthy control: diagnosis or history of facial pain such as tmd or tgn, history of migraine, history of any functional pain disorder: fibromyalgia, ibs, crps or recent chronic pain (within last month)
efficacy and safety study of desloratadine (mk-4117) in japanese participants with seasonal allergic rhinitis (mk-4117-204)

Conditions: Seasonal Allergic Rhinitis

Summary: this is an efficacy and safety study of desloratadine (mk-4117) in japanese participants with seasonal allergic rhinitis (sar). the primary hypothesis of this study is that the change from baseline in total nasal symptom score (tnss) is improved by desloratadine compared to placebo.

this study consists of a one-week symptom confirmation period during which participants undergo a single-blinded placebo run-in, a two-week double-blind treatment period and a two-week follow-up period.

Eligibility criteria:
inclusion criteria: * has at least a 2-year history of seasonal allergic rhinitis with typical symptoms * male or female who is unlikely to conceive: a surgically sterilized female, female who has reached natural menopause, or is of reproductive potential and agrees to either remain abstinent or use (or have her partner use) 2 acceptable methods of birth control from study start through 14 days after the last dose of study drug. exclusion criteria: * has a lower respiratory tract infection or has a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment * has a coexisting infection or systemic mycosis for which there are no effective antibiotics * has asthma that is under treatment and/or uncontrolled * has nasal septum ulcers, nasal surgery, or nasal trauma which have not healed * has vasomotor rhinitis or eosinophilic rhinitis * has a history of hypersensitivity to antihistamines or ingredients of study drug * has had treatment with corticosteroids (oral, injectable, suppository, depot drugs \[injectable\]) or immunological drugs within 28 days prior to visit 2 * is currently receiving treatment with another investigational drug or has received an investigational drug within prior 3 months * has started specific desensitization therapy (allergen immunotherapy) or nonspecific allassotherapy (histaglobin, vaccine therapy, etc.) or who has received such therapies within prior 3 months * has received coagulation or resection using laser therapy etc. for treatment for nasal symptoms * will receive nasal nebulizer therapy and/or thermotherapy during study period * has severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor * has a history of malignancy or clinically important hematological disorder, except for adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix * has a history of severe drug allergy (e.g. anaphylactoid reaction) * is pregnant or lactating or may be pregnant * is planning a remote trip for more than 1 day during the symptom confirmation period or for more than 2 days during the treatment period.
quality of life measures after single access vs conventional laparoscopic cholecystectomy: prospective randomized study.

Conditions: Evidence of Cholecystectomy

Summary: this study aimed to compare the short term outcomes between salc and conventional laparoscopic cholecystectomy (clc).

in a prospective study, two hundred fifty patients with symptomatic gall bladder stone were randomized to salc or conventional laparoscopic cholecystectomy (clc) (125 in each group). the primary endpoint of this study was to assess the total outcomes of quality of life using euroqol eq-5d questionnaire. the secondary endpoints were postoperative pain, analgesia requirement and duration, operative time, perioperative complications, estimated blood loss, hospital stay, cosmoses outcomes and number of days required to return to normal activities.

Eligibility criteria:
inclusion criteria: * gall bladder stones exclusion criteria: * acute cholecystitis * previous laparotomy * asa above 3
a study of abemaciclib (ly2835219) in native chinese participants with advanced and/or metastatic cancers

Conditions: Advanced Cancer; Metastatic Cancer

Summary: the purpose of this study is to determine the safety of the study drug known as abemaciclib in native chinese participants with advanced and/or metastatic cancers.


Eligibility criteria:
inclusion criteria: * the participant must have histological or cytological evidence of cancer which is advanced and/or metastatic, and is an appropriate candidate for experimental therapy in the judgment of the investigator, after available standard therapies have ceased to provide clinical benefit. * have the presence of measureable disease as defined by the response evaluation criteria in solid tumors (recist 1.1). * are native chinese men or women. * have adequate organ function, including: * hematologic: absolute neutrophil count (anc) ≥1.5 x 109/liters (l), platelets ≥100 x 109/l, and hemoglobin ≥9 grams per deciliter. participants may receive erythrocyte transfusions to achieve this hemoglobin level or platelet transfusions to achieve platelet levels at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after transfusion. * hepatic: bilirubin ≤1.5 times upper limits of normal (uln), alanine aminotransferase (alt), and aspartate aminotransferase (ast) ≤3.0 times uln. * renal: serum creatinine ≤1.2 milligrams per deciliter (mg/dl) for males or ≤1.0 mg/dl for females. * have a performance status ≤1 on the eastern cooperative oncology group (ecog) scale. * recovered from the acute effects of therapy (treatment- related toxicity resolved to baseline) except for residual alopecia. * have an estimated life expectancy of ≥12 weeks. exclusion criteria: * have received previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) within 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug. * have an acute leukemia or other relevant cancers at the discretion of the investigator. * females who are pregnant or lactating. * participants consuming drugs or foods that are known to be inducers (for example, grapefruit juice, phenytoin, carbamazepine) or strong inhibitors of cyp3a4 should be excluded during cycle 1. * have history or evidence of central nervous system (cns) malignancy or metastasis. screening of asymptomatic participants without history of cns metastases is not required for enrollment.

Keywords: cdk4/6 inhibitor
web-based weight loss intervention

Conditions: Overweight and Obesity

Summary: excess weight is a major risk factor underlying leading causes of death globally, including cardiovascular disease, type 2 diabetes, and some cancers. among participants assigned to the same lifestyle intervention arms in prior weight loss randomized controlled trials, large inter-individual differences in weight loss success have been observed, ranging from \>50lbs of weight loss to \>10lbs of weight gain. both genetic and non-genetic factors underlying differential adherence and weight loss success are poorly understood.

23andme aims to recruit 91,227 adults to participate in a web-based weight loss intervention. primary aims include: a.) to confirm whether ag/gg individuals at mtif3 rs1885988 lose more weight on lifestyle interventions; and b.) to test the performance of a randomized controlled trial vs. self-selection study design in terms of weight loss, drop-outs, and adherence. secondary (exploratory) analyses will focus on discovery of genetic and non-genetic predictors of weight loss success overall, and examination of potential interactions by intervention type. web-administered intervention content, videos, and forums will be surfaced to participants every two weeks, and self-reported surveys will be surfaced weekly for the active intervention duration.

Eligibility criteria:
inclusion criteria: * us-based men and women in self-reported 'good' or better health * consented to participate in research * bmi 25-40 kg/m2 * not actively on a weight loss plan * willing and able to modify eating and physical activity patterns * not under a doctor's care for a serious medical condition exclusion criteria: * are pregnant, lactating, within 6 months postpartum, or planning to become pregnant in the next 6 months * have diabetes (type 1 or 2) or are on hypoglycemic medications * had a heart attack or stroke within the past year * are unable or unwilling to follow a physical activity or diet intervention due to a medical condition or doctor's orders * have an eating disorder * have severe depression, anxiety, or other psychiatric conditions

Keywords: nutrition, diet, genetics, physical activity, weight loss
clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of a recombinant fviii in patients with severe hemophilia a

Conditions: Hemophilia A

Summary: this is a clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhfviii, a newly developed human cell-line derived recombinant fviii concentrate in previously treated patients with severe hemophilia a.


Eligibility criteria:
inclusion criteria: * severe hemophilia a (fviii:c \<= 1%) * male subjects between 12 and 65 years of age * body weight 25 kg to 110 kg * previously treated with fviii concentrate for at least 150 eds exclusion criteria: * other coagulation disorder than hemophilia a * present or past fviii inhibitor activity
the ehealth diabetes remission trial - pilot study

Conditions: Type 2 Diabetes

Summary: ten study participants will consume a low-calorie total diet replacement for 12 weeks, have a 6-week food reintroduction phase (week 13-18) and continue with the weight loss maintenance phase until the end of the study (week 19-26). the weight loss goal is 15 kg (or 15% if body weight is bellow 80 kg). the primary study outcome iw weight loss after 6 months and the co-primary outcome is diabetes remission after 6 months (hba1c \< 48 mmol/mol). during the weight maintenance phase, if weight regain occurs or if hba1c increases a rescue plan of total diet replacement will be recommended. the participants will be supplied with the total diet replacement modifast free of charge. participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor. participants will be advised to measure body weight, blood glucose and blood pressure every morning. the results are registered in the mobile phone application telia health monitoring and are wirelessly transmitted to the project's physician, nurse and dietician. at the beginning of the food reintroduction phase the participants will receive an activity tracer and will be advised to increase their physical activity. primary and secondary outcome measures will be estimated at the beginning and after 3 and 6 months. at the end of the study, all participants will take part in an individual semi-structured interview to investigate the participants' experience of diabetes remission and of the ehealth contact with the healthcare provider. after participants have completed the study, they will be followed at least once per year by obtaining data on blood sugar, hba1c, body weight, blood pressure, medication usage and diabetes complications from the healthcare computer system.


Eligibility criteria:
inclusion criteria: * type 2 diabetes with diabetes duration 0 to 6 years * bmi 27-45 kg/m2 * owning a smartphone * hba1c 43-107 mmol/mol during the past 12 months (48-107 mmol/mol without blood sugar lowering medication) exclusion criteria: * insulin treatment * weight loss 5 kg or more during the past 6 months * treatment with weight loss medication * diagnosed eating disorder * egfr \< 30 ml/min/1.73m2 * substance abuse * cancer * myocardial infarction during the past 6 months * severe heart failure * pregnancy

Keywords: diabetes remission weight loss low-calorie diet ehealth
portion size and to-go container on dinner intake

Conditions: Obesity; Eating Behavior

Summary: this study investigated whether the provision of a to-go container influenced the portion size effect at a meal. following a screening visit, women came to the lab once a week for 4 weeks to eat a meal of multiple foods. at each visit, the portion size of the meal was varied in a counterbalanced order. prior to their first meal, women were randomly assigned to one of two groups: a group that would have their leftovers packaged to go (to-go group) and a group that did not have leftovers packaged (control group). women were instructed to eat ad libitum at the meals. they also answered questions about hunger and fullness as well as food characteristics before and after each meal. following the final meal, subjects completed a series of questionnaires assessing subject characteristics as well as food characteristics. it was hypothesized that the effect of portion size on intake would be attenuated in subjects who received a to-go container with the meal. in addition, we aimed to identify any subject characteristics that moderated or exacerbated the portion size effect. it was also of interest to determine whether the portion size effect on individual foods were influenced by food characteristics such as perceived value.


Eligibility criteria:
inclusion criteria: * regularly eats 3 meals/day * willing to avoid alcohol the day before and during test days * likes foods offered at test meals * body mass index 18 - 36 (kg/m\*m) exclusion criteria: * smokes * athlete in training * pregnant or breastfeeding * taking medication that may affect appetite or food intake * food allergies or dietary restrictions * currently have or recently been diagnosed with disease or disorder known to affect appetite

Keywords: portion size food intake energy intake food choice